NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.

PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production.

(3S, 4S)-PF-06459988 is the less active S enantiomer of PF-06459988, which is a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR). PF-06459988 exhibits excellent selectivity against EGFR wild-type due to its minimally reactive electrophile, which reduces the likelihood of off-target labeling.

Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT).

EGFR/HER2-IN-9 是一种 EGFR 和 HER2抑制剂，对 EGFR、EGFR T790M 和 HER2 的 IC50分别为 3.2、8.3 和 14 nM。

Imgatuzumab (RG 7160; GA201) 是一种针对表皮生长因子受体 (EGFR) 的人源化、糖基工程化 IgG1 单克隆抗体。该产物通过阻断 EGF 结合来抑制 EGFR 介导的信号传导（如 MAPK 和 PI3K 通路），并诱导受体内化。作为一种糖基工程化抗体，Imgatuzumab 增强了对 Fc gamma RIIIa 的亲和力，从而表现出强效的抗体依赖性细胞介导的细胞毒性作用 (ADCC)。它常用于研究 EGFR 高表达的实体瘤，且在与化疗药物联用时表现出增效作用。